Conference Coverage: ASCO Genitourinary Cancers Symposium Coverage from the American Society of Clinical Oncology Genitourinary Cancers Symposium, held February 8-10, 2018, in San Francisco, ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) ...

For patients to maintain or improve their quality of life through their cancer treatment, it is pivotal that they communicate with their health care team. Clinical trials remain the gold standard when ...

Siamak Daneshmand, MD, explores unmet needs in the bladder cancer treatment landscape at ESMO 2023. November 27th 2023EP. 2: Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023 An ...

SAN DIEGO, Feb. 14, 2019 /PRNewswire/ -- Decipher Biosciences (formerly GenomeDx Inc.), a leader in the field of urologic cancer genomics, today announced that it will present results from seven ...

Non-users of 5-alpha-reductase inhibitors had a nearly 2.6 times increased risk of pathologic progression than those who took the drugs. Men on active surveillance long-term who take 5-alpha-reductase ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology ...

Dr. Laurence Albiges discusses triplet therapies, highlighting which patients with RCC may garner the most benefit with this treatment intensification. Among patients with low-grade, intermediate-risk ...